Sioux Falls, S.D., March 13, 2020 – SAB Biotherapeutics (SAB), an immunotherapy company
that has harnessed the native immune response, announced today it is delaying
the timeline for development at the USD Discovery District for a minimum of one
“With the outbreak of COVID-19 and our unique ability to rapidly respond with potential treatments to emerging infectious disease, we have an obligation to leverage this capability to quickly develop a new therapeutic treatment for what has become a global pandemic. This adds to the many factors that have impacted our business over the last nine months and represents well the accelerated pace at which we’ve been moving.”
The company has recently announced a collaboration with global pharma leader CSL Behring and has begun work with the U.S. government on a rapid response capability in addition to developing its own clinical immunotherapy assets.
“There are a number of developments that have led us to the
decision to delay development of a new building,” said Eddie J. Sullivan, PhD.
“But we believe it’s the right decision for human health, for South Dakota and
for our business.”
SAB Biotherapeutics was announced as an anchor tenant at the district in June of 2018. The company was asked to take over as developer for the project in 2019 and formed Aurochs, LLC, a wholly-owned subsidiary for that purpose. Since that time, driven primarily by the growth of the company, the building planned for the district has increased significantly in scope and complexity, resulting in a significant amount of work.
“The USD Discovery District and its stakeholders are supportive in SAB’s commitment to engage in mitigating the impact of the recent outbreak of COVID-19 and will work diligently to maintain the status of the project when appropriate,” said Dr. Mark Brown, President & CEO of the USD Discovery District.
SAB will continue to work together with the other parties and plan with contractors to minimize any impacts to their businesses and maintain what is needed to ramp back up. In the meantime, SAB is expediting the increased capacities needed to meet interim activity demands through other avenues and will announce when plans are solidified.
“As the result of years of hard work, we have an opportunity right now to show the world what we can do,” added Sullivan, “This extends to a larger vision we have for our company and quite frankly for biotech in South Dakota and its potential impact around the world.”
About SAB Biotherapeutics,
SAB Biotherapeutics, Inc. headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.